No augmentation of indoleamine 2,3 ‐dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients

Clinical&Experimental Immunology, EarlyView.

https://onlinelibrary.wiley.com/doi/abs/10.1111/cei.13093?af=R

Source: Clinical and Experimental Immunology - February 2, 2018 Category: Allergy & Immunology Source Type: research

More News: Allergy & Immunology | Liver | Liver Transplant | Transplant Surgery | Transplants | Urology & Nephrology